+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Multidrug-resistant Tuberculosis Therapeutics Market by Drug Class (Bedaquiline, Clofazimine, Isoniazid), Route Of Administration (Injectable, Oral), Treatment Type, Treatment Regimen Duration, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Multidrug-resistant Tuberculosis Therapeutics Market by Drug Class (Bedaquiline, Clofazimine, Isoniazid), Route Of Administration (Injectable, Oral), Treatment Type, Treatment Regimen Duration, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Multidrug-resistant Tuberculosis Therapeutics Market by Drug Class (Bedaquiline, Clofazimine, Isoniazid), Route Of Administration (Injectable, Oral), Treatment Type, Treatment Regimen Duration, End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5968090
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The multidrug-resistant tuberculosis therapeutics market has entered a critical phase, shaped by breakthroughs in treatment modalities and increasing strategic collaboration among global healthcare stakeholders. This evolution is driven by the need for innovative approaches to overcoming drug resistance, supporting decision-makers as they navigate a complex landscape of regulatory shifts, technological innovation, and evolving clinical demands.

Market Snapshot: Growth Dynamics in Multidrug-Resistant Tuberculosis Therapeutics

The multidrug-resistant tuberculosis therapeutics market grew from USD 370.53 million in 2024 to USD 411.00 million in 2025. Continuing to expand at a CAGR of 11.19%, it is projected to reach USD 700.58 million by 2030. This growth reflects advancing medical technologies, increased global awareness, and renewed public health prioritization. Market momentum is underpinned by the persistent challenge of resistance to existing drug regimens, setting the stage for new compounds and collaborative innovations that address both efficacy and accessibility.

Scope & Segmentation

This research analyzes the continuously evolving landscape of multidrug-resistant tuberculosis therapeutics, including:

  • Drug Class: Bedaquiline, Clofazimine, Isoniazid, Linezolid, Rifampin
  • Route of Administration: Injectable, Oral
  • Treatment Type: Medication-Based Treatments, Non-Medication Therapies
  • Treatment Regimen Duration: Long-Course Regimens, Short-Course Regimens
  • End User: Hospitals, Specialty Clinics
  • Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
  • Regional Focus: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (including China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Innovative Technology Use: Molecular diagnostics, digital health platforms for adherence, integrated supply chain management
  • Key Companies: GlaxoSmithKline plc, Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Abcam Limited, Eli Lilly and Company, Lupin Limited, Macleods Pharmaceuticals Ltd., Merck & Co., Inc., Mylan N.V., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi SA, WebMD LLC, Viatris Inc.

Key Takeaways for Senior Decision-Makers

  • Updating treatment protocols remains essential as resistance patterns evolve; embracing novel agents is enabling precision-targeted care for high-risk populations.
  • Molecular diagnostics and digital adherence tools are optimizing therapy selection and improving patient follow-up, leading to more predictable treatment outcomes.
  • Regional diversity necessitates tailored strategies, as healthcare infrastructure, distribution channels, and clinical priorities differ widely across Americas, Europe, Middle East & Africa, and Asia-Pacific.
  • Supply chain resilience is taking priority in the face of regulatory and geopolitical pressures, propelling industry actors to pursue localized manufacturing and diversified sourcing strategies.
  • Public-private partnerships and multi-sector collaborations are accelerating both research pipelines and access initiatives, ensuring that innovations move swiftly from discovery to clinical application.
  • Adjunctive therapies such as nutritional support and psychosocial counseling are increasingly recognized as critical complements to medication, supporting treatment completion and long-term outcomes.

Tariff Impact: Navigating US Policy Changes in 2025

New United States tariffs on pharmaceutical imports, effective from 2025, are shaping the therapeutic development and distribution landscape for multidrug-resistant tuberculosis. Increased duty rates on components and ingredients have required manufacturers to reevaluate sourcing, streamline customs procedures, and sometimes pursue supply chain localization. Although these policies introduce new administrative challenges and extend shipment timelines, they also encourage industry innovation in logistics and regional capacity-building, supporting continuity in global treatment access.

Methodology & Data Sources

This report integrates secondary literature, regulatory filings, and policy analysis with in-depth primary interviews with experts across clinical, research, and supply chain domains. Data triangulation techniques ensure findings are corroborated, while qualitative and quantitative approaches help elucidate market and therapeutic trends. All research followed clear ethical and confidentiality standards.

Why This Report Matters

  • Enables senior leaders to anticipate market shifts, adjust commercial strategies, and respond proactively to drug resistance challenges.
  • Supports informed product development, investment prioritization, and operational planning through detailed segmentation, competitive analysis, and policy assessment.
  • Empowers decision-makers to navigate supply chain disruptions and regulatory changes, ensuring uninterrupted access to critical therapies worldwide.

Conclusion

The multidrug-resistant tuberculosis therapeutics market is evolving rapidly, guided by new treatment paradigms, technological integration, and enhanced stakeholder collaboration. Executives equipped with comprehensive insights are best positioned to drive sustainable impact across the value chain and contribute to improved global health outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Growing adoption of all-oral bedaquiline and delamanid regimens to replace injectable therapies
5.2. Regulatory pathways accelerating approval of novel compounds in multidrug-resistant TB treatment
5.3. Integration of rapid molecular diagnostics and digital adherence technologies in personalized TB therapy
5.4. Emergence of fixed-dose combination therapies shortening treatment duration for multidrug-resistant TB patients
5.5. Price negotiation initiatives and donor-funded programs improving access to bedaquiline in low-income countries
5.6. Clinical trial data on novel nitroimidazole pretomanid combinations informing updated WHO treatment guidelines
5.7. Development of host-directed therapies alongside antibiotic regimens to reduce lung damage and improve outcomes
5.8. Use of artificial intelligence models to predict TB drug resistance and optimize personalized MDR-TB regimens
5.9. Scale-up of point-of-care therapeutic drug monitoring to personalize dosing in multidrug-resistant TB treatments
5.10. Development of inhaled antimicrobial formulations for targeted pulmonary delivery in challenging MDR-TB cases to reduce systemic toxicity
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Multidrug-resistant Tuberculosis Therapeutics Market, by Drug Class
8.1. Introduction
8.2. Bedaquiline
8.3. Clofazimine
8.4. Isoniazid
8.5. Linezolid
8.6. Rifampin
9. Multidrug-resistant Tuberculosis Therapeutics Market, by Route Of Administration
9.1. Introduction
9.2. Injectable
9.3. Oral
10. Multidrug-resistant Tuberculosis Therapeutics Market, by Treatment Type
10.1. Introduction
10.2. Medication-Based Treatments
10.3. Non-Medication Therapies
11. Multidrug-resistant Tuberculosis Therapeutics Market, by Treatment Regimen Duration
11.1. Introduction
11.2. Long-Course Regimens
11.3. Short-Course Regimens
12. Multidrug-resistant Tuberculosis Therapeutics Market, by End User
12.1. Introduction
12.2. Hospitals
12.3. Specialty Clinics
13. Multidrug-resistant Tuberculosis Therapeutics Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacies
13.3. Online Pharmacies
13.4. Retail Pharmacies
14. Americas Multidrug-resistant Tuberculosis Therapeutics Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Multidrug-resistant Tuberculosis Therapeutics Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Multidrug-resistant Tuberculosis Therapeutics Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. GlaxoSmithKline plc
17.3.2. Johnson & Johnson Services Inc.
17.3.3. F. Hoffmann-La Roche Ltd
17.3.4. Abcam Limited
17.3.5. Eli Lilly and Company
17.3.6. Lupin Limited
17.3.7. Macleods Pharmaceuticals Ltd.
17.3.8. Merck & Co., Inc.
17.3.9. Mylan N.V.
17.3.10. Novartis AG
17.3.11. Otsuka Pharmaceutical Co., Ltd.
17.3.12. Pfizer Inc.
17.3.13. Sanofi SA
17.3.14. WebMD LLC
17.3.15. Viatris Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET: RESEARCHAI
FIGURE 28. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET: RESEARCHSTATISTICS
FIGURE 29. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET: RESEARCHCONTACTS
FIGURE 30. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY BEDAQUILINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY BEDAQUILINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY CLOFAZIMINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY CLOFAZIMINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ISONIAZID, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ISONIAZID, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY LINEZOLID, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY LINEZOLID, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY RIFAMPIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY RIFAMPIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION-BASED TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION-BASED TREATMENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY NON-MEDICATION THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY NON-MEDICATION THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY LONG-COURSE REGIMENS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY LONG-COURSE REGIMENS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SHORT-COURSE REGIMENS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SHORT-COURSE REGIMENS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 69. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 70. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 81. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 82. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 83. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 84. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 85. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 86. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 87. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
TABLE 88. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
TABLE 89. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 90. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 91. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 92. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 93. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 94. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 95. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 96. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 97. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 98. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 99. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
TABLE 100. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
TABLE 101. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 102. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 103. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 104. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 105. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 106. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 107. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 108. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 109. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 110. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 118. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 119. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 120. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 121. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 122. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 144. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 146. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 148. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 152. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 154. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 155. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 156. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 157. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 158. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 159. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 160. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 161. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
TABLE 162. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
TABLE 163. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 164. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 165. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 168. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 169. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 170. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 171. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 172. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 173. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
TABLE 174. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
TABLE 175. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 176. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 177. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 178. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 179. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 180. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 181. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 182. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 183. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 184. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 185. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
TABLE 186. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
TABLE 187. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 188. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 189. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 190. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 191. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 192. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 193. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 194. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 195. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 196. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 197. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
TABLE 198. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
TABLE 199. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 200. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 201. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 202. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 203. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 204. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 205. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 206. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 207. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 208. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 209. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
TABLE 210. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
TABLE 211. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 228. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 230. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 232. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 240. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 242. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 244. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
TABLE 246. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 248. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 252. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 253. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 254. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 255. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 256. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 257. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2024 (USD MILLION)
TABLE 258. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2025-2030 (USD MILLION)
TABLE 259. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. DENMARK MULTIDRUG-RESISTA

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Multidrug-resistant Tuberculosis Therapeutics market report include:
  • GlaxoSmithKline plc
  • Johnson & Johnson Services Inc.
  • F. Hoffmann-La Roche Ltd
  • Abcam Limited
  • Eli Lilly and Company
  • Lupin Limited
  • Macleods Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • WebMD LLC
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages197
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 411 Million
Forecasted Market Value ( USD ) by 2030 $ 700.58 Million
Compound Annual Growth Rate11.1%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Tuberculosis Drug Pipeline Analysis Report 2025 - Product Image

Tuberculosis Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Anti-Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Anti-Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Tuberculosis Therapeutics Market Report 2025 - Product Image

Tuberculosis Therapeutics Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Tuberculosis Treatment Drugs - Global Strategic Business Report - Product Image

Tuberculosis Treatment Drugs - Global Strategic Business Report

  • Report
  • 369 Pages
  • Global
From
Tuberculosis Epidemiology Forecast 2025-2034 - Product Image

Tuberculosis Epidemiology Forecast 2025-2034

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.